Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
In the midst of the thriving biopharmaceutical industry, the cell and gene therapy (CGT) sector has become a global focal point due to its innovation and immense potential. At the start of 2025, the financing market in this field demonstrated vibrant activity, with numerous companies accelerating the research, development, and application of cutting-edge technologies such as cell therapy, gene therapy, nucleic acid therapy, and stem cell therapy, all supported by strong capital inflows. From January to February, a series of eye-catching financing events occurred one after another, injecting robust momentum into the industry's development. Below, let us take an in-depth look at these financing updates.
On January 21, 2025, Imbioray (Hangzhou) Biomedical Co., Ltd. completed a nearly 100-million-yuan Series A+ financing round. This round was led by Huarui Investment, with participation from Tylon Investment, Sunzi Technology, Huayi Capital, and Binjiang 5050 Fund. The funds will be used to advance the registration and clinical projects of Class I innovative drugs, such as off-the-shelf natural killer cell therapies.Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. was established in 2014. The company's headquarters is located in the Tianhe High-Tech Industrial Park in Binjiang District, Hangzhou. Its research and development focus on enhancing and regulating the core of the human innate immune system, primarily concentrating on tumor immunotherapy and the treatment of immune-related diseases. The central focus includes immunocyte therapies such as CAR-NK and CAR-γδT, as well as bispecific antibody products.
Microglow Gene (Suzhou) Co., Ltd. recently completed a Pre-A round of financing, with a total financing amount reaching tens of millions of RMB. This round of financing was jointly invested by Guangzhou Industrial Investment Group and Guangzhou Youjiu Investment, and the funds will support Microglow Gene in advancing its epigenetic editing pipeline research.Suzhou Huiyi Biomedical Technology Co., Ltd. was founded in 2021,Focusing on the industrialization of new gene editing technologies such as epigenetic editing and base editing. The chief scientist is an expert among the first batch of high-level talents, and the team is highly experienced in the field of gene editing, successfully achieving the world's first correction of the β-thalassemia mutation gene at the embryonic level through gene modification in 2015.
On January 22, 2025, Suzhou Huiyi Biomedical Technology Co., Ltd. completed the first closing of its nearly RMB100 million Series A financing round, led by Guozhong Capital and participated by Nanjing Novozymes Biotechnology Co., Ltd. The proceeds will be used for clinical advancement of the company’s product pipeline, industrialization setup, and commercial promotion.Suzhou Huiyi Biomedical Technology Co., Ltd. was founded in 2021.Mainly focusing on the development of infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement based on mRNA technology.In 2023, industrial and commercial changes occurred, with the addition of new shareholders such as Shenzhen Shunying Private Equity Investment Fund Partnership (Limited Partnership).
On January 18, 2025, Inscinstech Intelligent Technology Co., Ltd. completed a C-round financing of several hundred million yuan, led by the Service Trade Innovation Development Guiding Fund, with participation from Yuanhe Holdings and the existing shareholder Luxin Venture Capital. The funds will be used for the innovative R&D of the company’s new product pipelines and the expansion of production capabilities.Inscinstech was founded in 2017,Focus on providing comprehensive solutions from upstream and downstream processes to laboratory analysis for biopharmaceutical CMC.Established two major R&D centers, with a production and manufacturing base of over 10,000 square meters in Suzhou. Core team members come from leading companies in the biopharmaceutical field. Branches have been set up in Beijing, Shanghai, Guangzhou, Wuhan, Chengdu, Hangzhou, and other cities, along with an overseas business department, serving over a thousand domestic and international clients. These include biotech companies, universities, and research institutes in fields such as antibodies, vaccines, CGT, nucleic acid drugs, and IVD.
Chengdu Meijiecell Biotechnology Co., Ltd. recently received a strategic investment of tens of millions of RMB from Beijing Zhongfa Gaojingshan Zhenxuan Venture Capital Fund, which is under the Beijing Zhongguancun Capital. This provides significant support for its development in the field of cell therapy.Chengdu Meijiesai'er was founded in 2015,Developed the "world's first GMP-grade gene-edited T-cell product," completed the world's first clinical trial of gene-edited cells in humans in collaboration with West China Hospital, with full Phase I clinical results published in the 2020 journal *Nature Medicine*. Established four GMP cell engineering and quality control rooms with independent property rights.
Beijing Yimiao Zhongguo Pharmaceutical Technology Co., Ltd. has recently completed a financing round of several hundred million RMB in its Series E. This round was led by the Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund, with participation from Taiping Healthcare Fund, Capital Development Group, Si Ji Qing Investment, Sunshine Nuohexin, and other professional institutions. The funds will be used to support the commercialization of the company's first self-developed CAR-T new drug, IM19.Yimiao神州 was founded in 2015,Dedicated to applying innovative gene and cell drug technologies to the treatment of malignant tumors. Independently developed next-generation CAR-T technology.Completed a strategic D+ round financing of several hundred million RMB in November 2022, with the total financing amount exceeding 500 million RMB in 2022.
On February 20, 2025, WuXi AppTec increased the registered capital of Shanghai WuXi ATU Biotechnology Co., Ltd. from 100 million yuan to 600 million yuan, representing a 500% increase, highlighting its emphasis on the CGT field and potentially shifting its business focus to China.
WuXi AppTec was founded in 2000.Providing integrated new drug research and development and production services for the global biopharmaceutical industry. Bringing breakthrough treatment solutions to patients, the service scope covers areas such as chemical drug research and development and cell and gene therapy research and production.
This shows that the CGT sector financing in January to February 2025 presents a prosperous scene. Many companies have successfully obtained financial support, which not only reflects the capital market's continued optimism about this field but also indicates that driven by capital, cell and gene therapy technologies are expected to achieve more breakthroughs in the future. From the clinical advancement of innovative drugs, to the research of cutting-edge technology pipelines, to the industrialization and commercialization layout of enterprises, every financing deal contributes to the development of the industry.
References: Publicly Available Information
